AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03530306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS9-PS6
Description: Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
Study NCT01003964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP
Description: Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
Study NCT01003964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP
Description: Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
Study NCT03682146 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostatectomy
Description: Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
Study NCT04199689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
Study NCT03524092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC
Study NCT03524092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mirikizumab SC
Description: Administered SC
Study NCT03524092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mirikizumab IV
Description: Administered IV
Study NCT03524092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC
Study NCT03524092 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo SC
Description: Administered SC
Study NCT03381274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
Study NCT03381274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
Study NCT03381274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
Study NCT04199689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline for Injection)
Description: 0.9% sodium chloride given as a 0.5-mL intramuscular injection
Study NCT00713401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions
Study NCT03315182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV9.CMV.hNAGLU
Description: Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study NCT02794740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: External Spray
Study NCT02794740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: External Spray
Study NCT04699305 — intervention group
Intervention type: DEVICE
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study NCT00330798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Description: Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
Study NCT00330798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ketorolac 0.4%
Description: Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 27 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 30 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 33 Months
Study NCT03494933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRT-P implantation
Description: Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
Study NCT03494933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D implantation
Description: Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
Study NCT04414046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
Study NCT00005967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study NCT02600676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS) - active
Description: TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
Study NCT02600676 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS) - placebo
Study NCT04136067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
Study NCT04136067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: One daily dose of 3.0 nmol/kg administered s.c. for 6 days
Study NCT01732328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium plus vitamin D
Study NCT02331628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT - Extracorporeal Shockwave Therapy
Description: Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine.
Study NCT00113919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
Study NCT02697708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium control diet
Description: No additional potassium.
Study NCT02697708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium gluconate diet
Description: 1000 mg K from potassium gluconate.
Study NCT02697708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Diet
Description: 1000 mg K from potatoes.
Study NCT02697708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: French Fries Diet
Description: 1000 mg K from French Fries.
Study NCT00420095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin 30/70
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
Study NCT00420095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro low mix
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
Study NCT03006315 — intervention group
Intervention type: DEVICE
Intervention: Garmin Vivofit device
Description: Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
Study NCT03006315 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mobile Health quality of life assessements
Study NCT03810495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone implant
Description: 1.8 g implant containing 60% naltrexone
Study NCT04157660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Oxygen application Supplemental oxygen via mask
Study NCT04157660 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham room air
Description: Room air will be applied via mask
Study NCT03818997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
Study NCT03835520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
Study NCT04255563 — intervention group
Intervention type: DEVICE
Intervention: DCB treatment
Description: DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
Study NCT06689709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum Alkaline Phosphatase Levels
Description: Venous blood was drawn from the patients
Study NCT02251470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBE Wii (EG)
Description: Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
Study NCT02251470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBE Control (CG)
Description: Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
Study NCT04448912 — intervention group
Intervention type: PROCEDURE
Intervention: Damage control surgery
Description: Surgery for non-traumatic abdominal emergencies using the damage control approach
Study NCT04448912 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional surgery
Description: Conventional surgery for non-traumatic abdominal emergencies
Study NCT03835520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molecular Target
Description: Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
Study NCT02354248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple stimulation technique
Description: Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
Study NCT02354248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple stimulation technique
Description: Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
Study NCT00550732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
Study NCT04286867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Moderation Mobile Application
Description: This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
Study NCT04286867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Moderation Drink Tracker
Description: This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
Study NCT02427620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06687109 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty
Study NCT06687109 — intervention group
Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty
Study NCT02853084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL2351
Description: The dose will be adjusted based on disease activities
Study NCT01639690 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells transduced with TNS9.3.55
Description: Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
Study NCT03637816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: Given PO
Study NCT03637816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03637816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03637816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01627197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery of percutaneous catheter system
Description: Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
Study NCT04101331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: weekly intravenous infusions of 200mg
Study NCT03889015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
Study NCT03889015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: xylitol chewing gum
Description: Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
Study NCT03191734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System
Description: Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
Study NCT04481438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupunch Exercises
Description: The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
Study NCT04193176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Administered twice daily as an oral tablet of 45 mg
Study NCT04193176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study NCT01027754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
Study NCT01027754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
Study NCT02529488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL
Description: Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study NCT00324857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid Video
Description: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.
Study NCT00324857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
Study NCT00324857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI plus Decision aid
Description: Patient viewed the video and then underwent MI.
Study NCT00324857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: patients received a booklet.
Study NCT02459600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instulling cyclopentolate drops in the eye
Description: measuring refraction with and wirthout cyclopentolate drops under general anesthesia
Study NCT04254679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Description: Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.
Study NCT04254679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-opioid analgesics
Description: Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.
Study NCT02688621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Only
Description: 18 month behavioral weight loss intervention delivered online
Study NCT02688621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet + Incentives
Description: 18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing